Legend Biotech
LEGN
15.25
-0.85
-5.28%
Legend Biotech
US · LEGN
#2374 by market cap
Listed 2020
15.25
-0.85
-5.28%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Quant vs Street three independent views, side by side
StockVane factor grade
D-
Momentum strategy signal
Strong Sell
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
✦ Quant Analyst Revision Trend how this is computed
Deteriorating
4
■ Upgrades■ Downgrades
- 0 upgrades vs 4 downgrades among tracked analyst rating changes.
- Most recent: Oppenheimer moved from Buy to Hold on 2026-08-12.
Analyst consensus 10 analysts
Buy
Avg price target 41.90 +174.8%
Price target rangecurrent 15.25
Low20.00
Avg41.90
High65.00
Buy 60%
Hold 40%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-11-13 | Evercore | -- | Hold | 20.00 |
| 2026-11-11 | Morgan Stanley | -- | Buy | 43.00 |
| 2026-11-11 | Goldman Sachs | -- | Buy | 34.01 |
| 2026-11-11 | H.C. Wainwright | -- | Buy | 65.00 |
| 2026-11-11 | Barclays | -- | Buy | 61.00 |
| 2026-11-11 | Oppenheimer | -- | Hold | 25.00 |
| 2026-11-10 | RBC Capital | -- | Buy | 50.00 |
| 2026-11-06 | Barclays | -- | Buy | 68.00 |
| 2026-11-05 | Piper Sandler | -- | Buy | 64.00 |
| 2026-11-05 | H.C. Wainwright | -- | Buy | 65.00 |
| 2026-11-05 | RBC Capital | -- | Buy | 56.00 |
| 2026-10-30 | H.C. Wainwright | -- | Buy | 65.00 |
| 2026-10-29 | H.C. Wainwright | -- | Buy | 65.00 |
| 2026-10-27 | UBS | -- | Hold | 24.00 |
| 2026-10-19 | H.C. Wainwright | -- | Buy | 65.00 |
| 2026-10-15 | H.C. Wainwright | -- | Buy | 65.00 |
| 2026-10-14 | Goldman Sachs | -- | Buy | 38.09 |
| 2026-10-14 | H.C. Wainwright | -- | Buy | 65.00 |
| 2026-10-13 | Barclays | -- | Buy | 68.00 |
| 2026-10-09 | J.P. Morgan | -- | Hold | 33.00 |
| 2026-10-08 | RBC Capital | -- | Buy | 56.00 |
| 2026-10-02 | UBS | -- | Hold | 24.00 |
| 2026-09-30 | H.C. Wainwright | -- | Buy | 65.00 |
| 2026-09-28 | H.C. Wainwright | -- | Buy | 65.00 |
| 2026-09-11 | Barclays | -- | Buy | 74.00 |
Price target trend monthly average, last 3 years
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-08-12 | Oppenheimer | Buy → Hold | 40.00 |
| 2026-07-24 | UBS | Buy → Hold | 28.00 |
| 2026-07-13 | J.P. Morgan | Buy → Hold | 35.00 |
| 2026-01-22 | TD Cowen | Buy → Hold | 21.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q3 | 2026-11-10 | -- | ±13.80% | -15.97% (beat) |
| 2026/Q2 | 2026-08-11 | -- | ±8.77% | +5.66% (in line) |
| 2026/Q1 | 2026-05-12 | -- | ±9.03% | +10.48% (beat) |
| 2025/Q4 | 2026-03-10 | -- | ±8.97% | +2.19% (in line) |
| 2025/Q3 | 2025-11-12 | -- | ±8.98% | -2.67% (in line) |
| 2025/Q2 | 2025-08-11 | -- | ±10.07% | -2.05% (in line) |
| 2025/Q1 | 2025-05-13 | -- | ±10.87% | -4.01% (in line) |
| 2024/Q3 | 2024-11-12 | -- | ±8.20% | +0.35% (in line) |
| 2024/Q2 | 2024-08-09 | -- | ±14.01% | -1.77% (in line) |
| 2024/Q1 | 2024-05-13 | -- | ±11.01% | -0.62% (in line) |
| 2023/Q4 | 2024-03-11 | -- | ±11.96% | +3.07% (in line) |
| 2023/Q3 | 2023-11-20 | -- | ±11.65% | -6.29% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-11-20 20:02:40 · For reference only, not investment advice and not tailored to your situation.
Legend Biotech discussion 0 comments